1. Home
  2. CGAU vs IRON Comparison

CGAU vs IRON Comparison

Compare CGAU & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Centerra Gold Inc.

CGAU

Centerra Gold Inc.

HOLD

Current Price

$21.77

Market Cap

3.2B

ML Signal

HOLD

Logo Disc Medicine Inc.

IRON

Disc Medicine Inc.

HOLD

Current Price

$80.38

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGAU
IRON
Founded
2002
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.9B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
CGAU
IRON
Price
$21.77
$80.38
Analyst Decision
Buy
Strong Buy
Analyst Count
3
11
Target Price
$16.67
$103.18
AVG Volume (30 Days)
1.4M
318.1K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
1.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$25.17
N/A
Revenue Next Year
$13.62
$283.52
P/E Ratio
$11.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.99
$40.00
52 Week High
$21.74
$99.50

Technical Indicators

Market Signals
Indicator
CGAU
IRON
Relative Strength Index (RSI) 75.62 61.10
Support Level $15.06 $70.73
Resistance Level N/A $82.65
Average True Range (ATR) 0.76 3.26
MACD 0.53 0.32
Stochastic Oscillator 92.30 78.01

Price Performance

Historical Comparison
CGAU
IRON

About CGAU Centerra Gold Inc.

Centerra Gold Inc is principally focused on operating, developing, exploring and acquiring gold and copper properties in North America, Turkey, and other markets world-wide. The company reportable operating segments are Oksut; Mount Milligan; and Molybdenum. It derives maximum revenue from Mount Milligan segment. Geographically, it operates in Turkey, United States, and Canada.

About IRON Disc Medicine Inc.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Share on Social Networks: